Cytosorbents’ (CTSO) Buy Rating Reiterated at D. Boral Capital

Cytosorbents (NASDAQ:CTSO)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a research note issued on Friday,Benzinga reports. They presently have a $10.00 price target on the medical research company’s stock.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reiterated a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a report on Monday, November 11th. StockNews.com assumed coverage on Cytosorbents in a report on Saturday, December 28th. They issued a “hold” rating for the company. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Stock Performance

NASDAQ CTSO opened at $0.92 on Friday. The company has a market cap of $50.31 million, a P/E ratio of -2.56 and a beta of 0.57. The company has a fifty day simple moving average of $0.92 and a 200 day simple moving average of $1.02. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $1.59. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06.

Institutional Trading of Cytosorbents

Large investors have recently bought and sold shares of the company. Atomi Financial Group Inc. purchased a new stake in shares of Cytosorbents during the 3rd quarter valued at approximately $51,000. Geode Capital Management LLC grew its position in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares in the last quarter. Finally, Sargent Investment Group LLC grew its position in shares of Cytosorbents by 4.9% in the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after purchasing an additional 67,181 shares in the last quarter. 32.87% of the stock is owned by hedge funds and other institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.